Last quarter (Q4 2022), Antisense Therapeutics Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Antisense Therapeutics Limited's net income was AU$―. See Antisense Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	-	AU$ 7.61M	AU$ 8.68M	AU$ 6.67M	AU$ 3.58M	AU$ 2.62M
Operating Income	-	AU$ -7.61M	AU$ -8.68M	AU$ -6.67M	AU$ -3.58M	AU$ -2.62M
Net Non Operating Interest Income Expense	-	AU$ 22.27K	AU$ -6.55K	AU$ 17.99K	AU$ 66.17K	AU$ 25.55K
Other Income Expense	-	AU$ 1.78M	AU$ 629.20K	AU$ 740.10K	AU$ 572.47K	AU$ 263.57K
Pretax Income	-	AU$ -5.81M	AU$ -8.06M	AU$ -5.91M	AU$ -2.94M	AU$ -2.33M
Tax Provision	-	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -5.81M	AU$ -8.06M	AU$ -5.91M	AU$ -2.94M	AU$ -2.33M
Basic EPS	-	AU$ >-0.01	AU$ -0.01	AU$ -0.01	AU$ >-0.01	-
Diluted EPS	-	AU$ >-0.01	AU$ -0.01	AU$ -0.01	AU$ >-0.01	-
Basic Average Shares	-	AU$ 634.29M	AU$ 540.98M	AU$ 455.83M	AU$ 386.10M	-
Diluted Average Shares	-	AU$ 634.29M	AU$ 540.98M	AU$ 455.83M	AU$ 386.10M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -5.81M	AU$ -8.06M	AU$ -5.91M	AU$ -2.94M	AU$ -2.33M
Normalized Income	-	AU$ -5.81M	AU$ -8.06M	AU$ -5.91M	AU$ -2.94M	AU$ -2.33M
Interest Expense	-	-	-	-	-	-
EBIT	-	AU$ -7.61M	AU$ -8.68M	AU$ -6.67M	AU$ -3.58M	AU$ -2.62M
EBITDA	-	AU$ -7.52M	AU$ -8.58M	AU$ -6.56M	AU$ -3.58M	AU$ -2.61M

Currency in AUD

Antisense Therapeutics Limited Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing